• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: BOSTON SCIENTIFIC CORPORATION SYNERGY; CORONARY DRUG-ELUTING STENT

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

BOSTON SCIENTIFIC CORPORATION SYNERGY; CORONARY DRUG-ELUTING STENT Back to Search Results
Model Number 10623
Device Problem Obstruction of Flow (2423)
Patient Problems Thrombosis (2100); No Code Available (3191)
Event Date 07/02/2020
Event Type  Injury  
Manufacturer Narrative
Date of event: used the 1st day of the month of the bsc aware date as no event date was provided.(b)(6).Device is a combination product.
 
Event Description
It was reported that patient experienced acute thrombosis.After placing a synergy drug-eluting stent, an acute thrombosis occurred.No further patient complications were reported.
 
Event Description
It was reported that patient experienced acute thrombosis.After placing a synergy drug-eluting stent, an acute thrombosis occurred.No further complications were reported.It was further reported that the 100% stenosed, 3.5x38mm, de novo, type c, thrombotic target lesion was located in the mid right coronary artery (rca).After aspirating thrombus of right posterior descending artery and mid rca, intravenous ultrasound (ivus) was performed and the lesion was pre-expanded with 3.5x10m wolverine cutting balloon.A 4.00x38mm synergy ii drug-eluting stent was placed at 14 atmospheres.After ivus confirmation, the procedure was completed.On the same day, a stent thrombus was found.As a treatment, an aspiration of thrombus was perfomed and additional dilatation was performed with a 4mm non-compliant balloon.No patient complications were reported and the patient's status was good.As per physician's comment, thrombocytosis was observed, suggesting that thrombocythemia may have caused thrombus in th stent.It was considered that it was more likely due to patient factors than thrombosis due to stent.
 
Manufacturer Narrative
(b3) date of event: updated from the 1st day of the month of the bsc aware date to 07/02/2020.(e1) initial reporter city: (b)(6).Device is a combination product.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
SYNERGY
Type of Device
CORONARY DRUG-ELUTING STENT
Manufacturer (Section D)
BOSTON SCIENTIFIC CORPORATION
two scimed place
maple grove MN 55311
MDR Report Key10328680
MDR Text Key200602190
Report Number2134265-2020-09251
Device Sequence Number1
Product Code NIQ
Combination Product (y/n)N
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type company representative,foreig
Type of Report Initial,Followup
Report Date 08/24/2020
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received07/27/2020
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Expiration Date03/24/2021
Device Model Number10623
Device Catalogue Number10623
Device Lot Number0024594065
Was Device Available for Evaluation? No
Date Manufacturer Received07/30/2020
Is This a Reprocessed and Reused Single-Use Device? No
Patient Sequence Number1
Patient Outcome(s) Other; Required Intervention;
Patient Age66 YR
-
-